Abstract
Introduction
The quality of medicines and healthcare products is a significant challenge these days, with counterfeiting accounting for at least 10% of all products in circulation worldwide, including in Africa. In the specific case of the Democratic Republic of Congo (DR Congo), which is the second-largest country on the continent and faces serious challenges in frontier control, the country has become a major hub for this scourge. Counterfeit medicines circulating within its territory account for over 20% of the pharmaceutical market.
Purpose
This research aimed to provide a simple, reliable, and economical method for quality control of drugs and healthcare products in the Congolese pharmaceutical market. This was achieved by developing and validating an ultraviolet-visible (UV-vis) spectrophotometric method for the simultaneous determination of paracetamol and ibuprofen in dosage forms.
Methods
From stock solutions, 0.65 ml of paracetamol and 0.8 ml of ibuprofen were transferred into volumetric flasks to prepare 10 ml of each solution. These solutions were separately scanned between 200-400 nm to observe the absorption maxima of each compound in UV-vis spectra against the blank (ethanol). Subsequently, individual solutions were prepared to obtain calibration and validation standards for the method validation, using the total error strategy and studying various validation criteria (specificity, precision, accuracy, linearity, robustness). After evaluating all the criteria, the developed and validated method was applied for the qualitative and quantitative analysis of dosage forms containing both paracetamol and ibuprofen.
Results
When solubilized in ethanol, paracetamol and ibuprofen exhibited absorption maxima at 249 nm and 219 nm, respectively. The method demonstrated strong correlation over the concentration ranges used (2.6–9.1 µg/ml for paracetamol and 3.2–9.6 µg/ml for ibuprofen). The correlation coefficients and regression lines determined at selected wavelengths were: y = 0.0924 x (R2 = 0.999) and y = 0.0228x (R2 = 0.9996) for paracetamol at 249 nm and 219 nm respectively, and y = 0.0429 x (R2 = 0.9993) for ibuprofen at 219 nm. The committed bias and the coefficient of variation in the precision study were within ±2% and less than 2%, respectively. Furthermore, the application of the method to dosage forms produced appropriate active ingredient rates, which ranged between 98% and 102%.
Conclusion
The developed method showed no interference between the active ingredients and the usual excipients used in tablet manufacturing. The recovery rates obtained in the selectivity and accuracy studies were consistently between 98% and 102%. Active ingredient contents determined by applying the method to pharmaceutical dosage forms ranged between 95% and 105%.
References
Aboud, K. M., Mohammad, A., Isbera, M., & Beesh, M. (2017). Development and validation UV spectrophotometric method for determination of atenolol in pure materials and pharmaceutical dosage. Indo American Journal of Pharmaceutical Research, 7(4).
Al-abdulrahman, M., Khaliffah, Y. A. B., Alhaily, M. B., Almutairi, A. F., Aldirbas, H. M., Almutairi, A. F., Alotaibi, N. O., Asiri, H. F., Ajlouni, A. W., Alhazmi, S. F., & Alotaibi, M. O. D. (2023). Detection methods of counterfeit drugs: A systematic review. Journal of Pharmaceutical Research and Report, 4(6), 1–9.
British Pharmacopoeia Commission. (2022). British Pharmacopoeia 2023 (print edition). The Stationery Office.
Dey, S., Pradhan, P., Upadhayay, U., Shah, S., & Goswami, K. (2012). UV spectrophotometric determination of cefixime in bulk and its dosage form. Journal of Pharmacy Research, 5(12), 5419–5422.
Douglas, A. Skoog, Holler, F. J., & Nieman, T. A. (2003). Principes d’analyse instrumentale. Ed. de Boeck.
Durgesh, R. P., Patil, M. P., Sonawane, S. S., & Jai, C. P. (2015). Development and validation of spectrophotometric method for estimation of mebendazole in bulk and pharmaceutical formulation. World Journal of Pharmaceutical Research, 4(7), 2223–2235.
Ermer, J., & Miller, J. H. (2005). Method validation in pharmaceutical analysis: A guide to best practice. Wiley-VCH.
International Conference on Harmonization (ICH). (1996). Guideline of technical requirements for registration of pharmaceuticals for human use: Q2B "Etape 4": Validation analytique. Pharmeuropa Guide Technique, 29–42.
International Conference on Harmonization (ICH). (2005). ICH harmonized tripartite guideline: Validation of analytical procedures: Text and methodology Q2 (R1).
Jain, P., Patel, M., & Surana, S. (2011). Development and validation of UV spectrophotometric method for determination of cefuroxime axetil in bulk and in formulation. International Journal of Drug Development & Research, 3(4), 318–322.
Mendham, J., Denney, R. C., Barnes, J. D., & Thomas, M. (2015). Analyse chimique quantitative de Vogel (6th ed.). Ed. de Boeck.
Mesheal, A., Khaliffah, Y. A. B., Alhaily, M. B., Almutairi, A. F., Aldirbas, H. M., Almutairi, A. F., Alotaibi, N. O., Asiri, H. F., Ajlouni, A. W., Alhazmi, S. F., & Dawi Alotaibi, M. O. (2023). Detection methods of counterfeit drugs: A systematic review. Journal of Pharmaceutical Research and Report, 4(6), 1–9.
OECD/EUIPO. (2020). Trade in counterfeit pharmaceutical products (pp. 16–22).
Skoog, D. A., West, D. M., Holler, F. J., & Crouch, S. R. (2015). Chimie analytique (3rd ed.; C. Buess-Herman, J. Dauchot, & T. Doneux, Trans.). Ed. de Boeck.
Sowajanya, G., Thota, D., Valli, S. V., Vaddi, P., & Seshagiri Rao, V. L. N. (2012). Development and validation of UV spectroscopic methods for simultaneous estimation of ciprofloxacin and tinidazole in tablet. International Current Pharmaceutical Journal, 1(10), 317–321.
US Federal Government, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), & Center for Biologics Evaluation and Research (CBER). (2001). Guidance for industry: Bioanalytical method validation (Rockville, MD, USA).
United States Pharmacopeial Convention. (2020). USP–NF 2021, Issue 1 (formerly USP 44–NF 39). United States Pharmacopeial Convention.
World Bank. (2005). Pharmaceuticals: Counterfeits, substandard drugs, and drug diversion. Health, Nutrition, and Population (HNP) Discussion Paper. Washington, DC: World Bank. Retrieved from https://documents.worldbank.org/en/publication/documents-reports/documentdetail/320051468135938535/pharmaceutical-counterfeits-substandard-drugs-and-drug-diversion
World Health Organization (WHO). (1993). Bulletin of the World Health Organization, 71. Retrieved from https://www.who.int/publications/journals/bulletin

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.